Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRhythm Technologies, Inc. (NASDAQ: IRTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer. As a digital health care company focused on ambulatory cardiac monitoring and data analytics, iRhythm uses its SEC reports to communicate financial performance, risk factors, governance matters, and material corporate events related to its Zio long-term continuous monitoring (LTCM) service and broader operations.
Investors can use this page to review current and historical filings retrieved from the SEC’s EDGAR system, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Recent 8-K filings have covered topics such as quarterly financial results, investor presentations, and amendments to the Executive Change in Control and Severance Policy, which outlines severance payments, COBRA coverage, and equity vesting treatment for senior leaders under specified termination scenarios.
For those analyzing iRhythm’s business in more depth, the company’s periodic reports typically discuss revenue from Zio services, gross margins, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted net loss, and liquidity metrics such as cash, cash equivalents, and marketable securities. These documents also describe how iRhythm accounts for items like stock-based compensation, business transformation costs, and other adjustments that affect non-GAAP results.
Stock Titan enhances access to these filings with AI-powered summaries that help explain the key points of lengthy documents, such as 10-K and 10-Q reports, in more accessible language. Users can quickly identify major changes in financial condition, updates to risk disclosures, and details of insider or executive-related arrangements that appear in forms and exhibits. This combination of real-time filing access and AI-generated insights can support investors, analysts, and other stakeholders who want to understand how iRhythm reports on its digital cardiac monitoring business and corporate governance over time.
iRhythm Holdings, Inc. reported higher Q1 2026 revenue but remained unprofitable. Revenue rose to $199.4 million, up from $158.7 million a year earlier, driven mainly by contracted commercial payors and Medicare. Net loss narrowed to $13.9 million, or $0.43 per share, compared with a $30.7 million loss, reflecting improved operating leverage.
The company ended the quarter with $240.1 million in cash and cash equivalents and $309.5 million in marketable securities, against $661.3 million of 1.50% senior convertible notes due 2029. Adjusted EBITDA turned positive at $14.1 million versus a negative $2.6 million a year earlier.
iRhythm continues to invest in internal-use software, strategic investments (including loans to BioIntelliSense), and stock-based compensation, while managing credit losses and contractual allowances on receivables. The company also discloses ongoing securities, patent, and government matters and states it is cooperating with authorities and defending these cases.
iRhythm Holdings reported strong first quarter 2026 results with revenue of $199.4 million, up 25.7% from $158.7 million a year earlier, driven by higher Zio service volumes and newer growth channels.
Gross profit rose to $141.4 million with gross margin improving to 70.9%, while operating expenses increased to $157.5 million as the company invested in growth and incurred litigation-related costs. Net loss narrowed to $13.9 million, or $0.43 per share, from $30.7 million, helped by operating leverage and non-GAAP adjustments that lifted adjusted EBITDA to $14.1 million.
Unrestricted cash, cash equivalents, and marketable securities totaled $549.6 million as of March 31, 2026, and the company raised full-year 2026 guidance to revenue of $875–$885 million with an adjusted EBITDA margin of 12%–13%, reflecting expectations for continued volume-led growth and margin expansion.
Vanguard Portfolio Management reports beneficial ownership of 1,824,090 shares of IRhythm Holdings Inc. The filing states this equals 5.64% of the class as of 03/31/2026, with Vanguard holding sole dispositive power for all 1,824,090 shares and sole voting power for 27,718 shares.
Vanguard Capital Management reported beneficial ownership of 1,691,483 shares of IRhythm Holdings Inc. common stock, equal to 5.23% of the class. The filer reports sole voting power over 245,773 shares and sole dispositive power over 1,691,483 shares. The filing is signed by Ashley Grim on 04/27/2026.
iRhythm Holdings, Inc. is asking stockholders to vote at a virtual 2026 annual meeting on May 27, 2026, including the election of nine directors and several key governance and compensation items.
The company seeks approval of a new 2026 Equity Incentive Plan reserving 1,690,000 shares, which will succeed its 2016 plan, plus ratification of KPMG as auditor, an advisory say-on-pay vote, and an amended and restated certificate of incorporation for subsidiary iRhythm Technologies, Inc. to remove a pass-through voting provision.
iRhythm highlights 2025 performance, including revenue of $747.1 million, 26.2% year-over-year growth, first-ever positive quarterly GAAP net income, first full year of positive free cash flow, adjusted EBITDA of $68.9 million (9.2% of revenue), and year-end cash, cash equivalents and marketable securities of $583.8 million.
The proxy also emphasizes an independent, skills-diverse board, robust risk oversight (including AI and cybersecurity), and sustainability efforts such as a 92.3% landfill waste diversion rate and completion of a Scope 3 greenhouse gas emissions inventory.
iRhythm Holdings, Inc. executive Julianne Rodda, EVP and Chief People Officer, filed an initial Form 3 reporting her beneficial ownership of the company’s Common Stock. The filing shows direct ownership of 20,313 shares, including 17,047 restricted stock units (RSUs) subject to future vesting.
The 17,047 RSUs are scheduled to vest in tranches of 3,863 on August 1, 2026, 1,074 on February 28, 2027, 4,094 on March 1, 2027, 1,074 on February 29, 2028, 2,782 on March 1, 2028, 2,781 on March 1, 2029, and 1,379 on March 1, 2030, contingent on her continued service. Each RSU represents a contingent right to receive one share of Common Stock.
iRhythm Holdings, Inc. is asking stockholders to elect nine directors and vote on five proposals at its virtual 2026 Annual Meeting on May 27, 2026. The board recommends approval of a new 2026 Equity Incentive Plan reserving 1,690,000 shares, adoption of a Restated Certificate of Incorporation to remove a pass-through voting provision, ratification of KPMG LLP as auditor, and a non-binding advisory vote on named executive officer compensation. The company highlights 2025 results including $747.1 million revenue (26.2% year-over-year growth), over 2.5 million patient reports, improved gross margin (+170 basis points year-over-year), first positive quarterly GAAP net income in Q4 2025, and year-end unrestricted cash and investments of $583.8 million. The proxy also details governance, board composition, sustainability achievements, cybersecurity oversight, and director compensation.
iRhythm Holdings, Inc. reported that its Audit Committee dismissed PricewaterhouseCoopers LLP as its independent registered public accounting firm on March 30, 2026 and approved the engagement of KPMG LLP for the audit of the fiscal year ending December 31, 2026.
Pwc’s audit reports on the company’s consolidated financial statements for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications relating to uncertainty, audit scope, or accounting principles, and the company states there were no disagreements or reportable events with PwC during those periods or through March 30, 2026.
The company provided PwC with a copy of the report and requested a response letter to the U.S. Securities and Exchange Commission; PwC agreed with the company’s statements, and this letter is included as Exhibit 16.1 dated March 31, 2026.
The Vanguard Group filed Amendment No. 7 to a Schedule 13G/A reporting 0 shares of iRhythm Holdings Inc. common stock as of 03/13/2026. The filing explains an internal realignment on January 12, 2026 that caused certain Vanguard subsidiaries and business divisions to report beneficial ownership separately. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
iRhythm Holdings filed a Schedule 13G reporting that Millennium Management LLC and related filers beneficially own 1,664,203 shares of Common Stock, representing 5.1% of the class. The filing states these shares are held by entities over which Millennium and related managers have shared voting and dispositive power.
The filing is a joint filing by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander and includes a Joint Filing Agreement dated March 20, 2026.